netFormulary Harrogate & Rural District Formulary NHS
Harrogate & District NHS Foundation Trust
Harrogate & Rural District Clinical Commissioning Group
 
 
 Search
 Formulary Chapter 13: Skin - Full Chapter
Notes:


 Details...
13.05.03  Expand sub section  Drugs affecting the immune response
Adalimumab (Humira)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Initiation by consultant Dermatologist only

 
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Azathioprine
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber Shared Care

Tablets 25mg, 50mg

This is to be used with the shared care guidelines - see link.

* Note this is for an UNLICENSED indication*

 
Link  Azathioprine Shared Care Guideline
   
Ciclosporin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber Shared Care
Due to differences in bioavailability, patients must remain on the same brand of immunosuppressant except on the advice of specialist clinician. MUST be prescribed by brand. 
Link  Ciclosporin Shared Care Guidelines
Link  NICE CG153: Psoriasis - assessment and management
   
Dupilumab (Dupixent)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
For use by Consultant Dermatologists only - for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. 
   
Etanercept (Benapali)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Initiation by a consultant Dermatologist only

 
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Etanercept (Enbrel )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Homecare

Initiation by consultant Dermatologist only

 
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Guselkumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Grey

Added as NICE TA521 available - see link

Not yet approved by the APC

 
Link  NICE TA521 Guselkumab for treating moderate to severe plaque psoriasis
   
Methotrexate
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber Shared Care
 
Link  British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016
Link  NICE CG153: Psoriasis - assessment and management
   
Pimecrolimus (Elidel)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted  
   
Tacrolimus (Protopic)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
 
   
Ustekinumab (Stelara)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Homecare
 
Link  NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Link  NICE TA340: Ustekinumab for treating active psoriatic arthritis
Link  - TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Link  NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
   
 ....
 Non Formulary Items
Ciclosporin  (Sandimmun)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Efalizumab  (Raptiva)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines which are suitable to be prescribed in primary care only after specialist recommendation. Ongoing prescribing by primary care includes titration of dose and assessment of efficacy. There is no need for ongoing monitoring other than for general adverse effects as listed in the BNF & SPC.  

Amber Shared Care

Medicines which are suitable to be prescribed in primary care only after specialist recommendation only under a shared care protocol once the patient has been stabilised. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must be approved by the Harrogate & Rurual District Area Prescribing Committee (HaRD APC).   

Black

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) has reviewed and does not recommend for use at present based on a review of clinical and/or cost effectiveness data.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with nationally recognised formularies e.g. BNF, BNF for Children, Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.  

Grey

Medicines which the Harrogate & Rural District Area Prescribing Committee (HaRD APC) have not yet reviewed.   

Red

Medicines for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician. The drug should be supplied by the hospital for the duration of the treatment course. Primary care prescriber initiation or continuation of treatemnt is not recommended.  

netFormulary